The latest updates in hemonc research

The 23rd Congress of the European Hematology Association (EHA) 2018, took place on the 14–17 June in Stockholm, Sweden. EHA 2018 brought together leading experts in hematological oncology from around the world, who presented the latest updates in key areas.

Highlights in hematological oncology from this year’s conference include promising results from many clinical trials, including DESTINY and CAPTIVATE, advances in the use of biomarkers to detect disease and inform treatment strategy, and the latest applications of immunotherapy.

View all videos

EHA 2018

European Hematology Association 23rd Congress

14–17 June 2018 | Stockholm, Sweden

The latest updates in hemonc research

The 23rd Congress of the European Hematology Association (EHA) 2018, took place on the 14–17 June in Stockholm, Sweden. EHA 2018 brought together leading experts in hematological oncology from around the world, who presented the latest updates in key areas.

Highlights in hematological oncology from this year’s conference include promising results from many clinical trials, including DESTINY and CAPTIVATE, advances in the use of biomarkers to detect disease and inform treatment strategy, and the latest applications of immunotherapy.

View all videos

Incorporating novel therapies into frontline ALL treatment

Oliver Ottmann • 14 Jun 2018

Promising outlook for frontline blinatumomab in Ph+ ALL

Giovanni Martinelli • 14 Jun 2018

Ibrutinib for CLL within a population-based setting: a promising outlook

Lina van der Straten • 14 Jun 2018

Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?

Arnon Kater • 14 Jun 2018

DESTINY: achieving TFR by de-escalating therapy in CML

Richard Clark • 14 Jun 2018

The importance of achieving early molecular response in CML

Timothy Hughes • 14 Jun 2018

Early MRD negativity predicts depth of response to CAR T-cells in R/R MM

Nikhil Munshi • 14 Jun 2018

Promising outlooks for venetoclax combinations for MM

Shaji Kumar • 14 Jun 2018

Venetoclax: an unmet need in R/R mantle cell lymphoma after BTK inhibitors

Toby Eyre • 14 Jun 2018

Novel drug combinations for Hodgkin lymphoma: more effective & less toxic

Anna Sureda • 14 Jun 2018

Treatment challenges in myelofibrosis

Claire Harrison • 14 Jun 2018

Targeting CD123 to treat myelofibrosis and CMML

Naveen Pemmaraju • 14 Jun 2018

Do results obtained in clinical trials translate accurately in real world practice?

Paul Richardson • 14 Jun 2018

Genetic profiling for high-risk MM is practical in a short timeframe

Matthew Jenner • 14 Jun 2018

FORTE: effective treatment of newly diagnosed MM with KRd

Francesca Gay • 14 Jun 2018

Multiple Myeloma trial highlights: ARROW, OPTIMISMM & ALCYONE

Mohamad Mohty • 14 Jun 2018